Top Markets
#1 Akedo Akedo +55.87%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +47.84%
#4 Velvet Velvet +37.51%
#5 Black Phoenix Black Phoenix +34.10%
#6 Cross Cross +28.39%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.20%
#8 QANplatform QANplatform +14.28%
#9 Perle Perle +13.52%
#10 OVERTAKE OVERTAKE +13.48%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Enveric Biosciences, Inc. Enveric Biosciences, Inc.

Enveric Biosciences, Inc.

ENVB
Rank in Stocks #38575
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse... Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Share Price
$1.48
Market Cap
$883.58K
Change (1 day)
-1.99%
Change (1 year)
-88.89%
Country
US
Trade Enveric Biosciences, Inc. (ENVB)

Category

Healthcare
Revenue for Enveric Biosciences, Inc. (ENVB)
Revenue in Aug 2026 TTM: 0
According to Enveric Biosciences, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Enveric Biosciences, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE